Xeris Biopharma stockXERS
Xeris Biopharma trades at $13.08, 4.8% below its 52-week high (Nov 5, 2026). The price is above its 50- and 200-day averages, i.e. in an uptrend. +66.6% year to date, +32.5% over 12 months (S&P 500 over the same period: +8.8%). Next earnings report: Nov 5, 2026.
- Market pulseXeris Biopharma tops Q3 EPS and revenue estimates, raises 2026 revenue outlook to $395–$405 million
- Market pulseXeris Biopharma CEO accelerates Recorlev outlook, now sees nearly $1B annual sales 3–4 years earlier, supporting higher 2030 revenue view
- Business WireXeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
The trigger was the quarterly report: EPS +1,124% year over year, 89.5% above the estimate.
All moves of the day →Ratings, candles, signals and the screener for XERS — after you log in
Open the terminalFrequently asked questions about Xeris Biopharma
What is the Xeris Biopharma stock price?
At the close on Nov 5, 2026: $13.08 (+25.05% on the day). 52-week high: $13.74 on Nov 5, 2026. During the session the price is updated with a 15-minute delay, after the close with the day's final figures.
When does Xeris Biopharma report earnings?
The next quarterly report is on Nov 5, 2026. Last quarter, earnings per share changed +1,124% year over year, revenue +44%.
Does Xeris Biopharma pay dividends?
No, Xeris Biopharma does not pay dividends.
Where does Xeris Biopharma trade and how to buy it?
Ticker XERS, exchange Nasdaq, listed since 2018. You can buy it through a broker with access to US exchanges.
Should I buy Xeris Biopharma now?
We do not give buy or sell advice. Ratings, the detailed chart and signals for XERS are in the terminal after you log in.